6533b835fe1ef96bd129fe6a
RESEARCH PRODUCT
2 years in the life of COPD patients: Evolution of GOLD 2011 classification in the 'real-life' DACCORD study
N LossiHeinrich WorthCarl-peter CriéeClaus VogelmeierRoland BuhlPeter KardosClaudia Mailändersubject
COPDPediatricsmedicine.medical_specialtyCopd patientsbusiness.industryMean agemedicine.diseaseLower riskSecondary caremedicineCopd assessment testObservational studybusinessProgressive diseasedescription
Introduction Limited data are available on the progression of COPD categorised according to GOLD 2011. We analysed data from the ongoing, non-interventional, observational DACCORD study and compared baseline GOLD 2011 categorisation with that of 1 and 2-years after inclusion. Methods Patients with a diagnosis of COPD were recruited into DACCORD following either a change or initiation of maintenance medication. Baseline exacerbations data (collected over 6 months) were annualised for GOLD categorisation at baseline; COPD symptoms were evaluated using the COPD Assessment Test (CAT) at baseline as well as the 1 year and 2 year visit. Data on exacerbations were collected every 3 months up to 2 years. Results 3315 patients have completed the 2 year follow-up (58.6% male, mean age 65.6 years) in 349 primary or secondary care centres. In the GOLD 2011 analysis, there was a general shift to lower risk categories from baseline to Year 1, mainly due to a lower number of exacerbations in Year 1; overall categorisation then remained relatively stable from Year 1 to Year 2. This resulted in a sustained decrease in the percentage of Category D patients. Conclusions COPD is generally considered to be a progressive disease. This analysis of 9real life9 data shows that the large majority of COPD patients do not exacerbate, and suggests that that long-term clinical stability can be achieved.
year | journal | country | edition | language |
---|---|---|---|---|
2016-09-01 | 6.1 Epidemiology |